Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Shipp · SciRah

Researcher profile · Semantic Scholar

M. Shipp

Share profile

M. Shipp — researcher profile on SciRah

h-index: 94
Works: 339
Citations: 49K

Most-cited papers

Molecular Subtypes of Diffuse Large B-cell Lymphoma are Associated with Distinct Pathogenic Mechanisms and Outcomes
B. Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim +42 more
2018Nature Medicine1,739 citations Open access
Semantic Scholar
The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee.
E. Campo, E. Jaffe, J. Cook, L. Quintanilla-Martinez +68 more
2022Blood1,447 citations Open access
Semantic Scholar
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
A. Lesokhin, S. Ansell, P. Armand, E. Scott +19 more
2016Journal of Clinical Oncology946 citations Open access
Semantic Scholar
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Robert Chen, P. Zinzani, M. Fanale, P. Armand +13 more
2017Journal of Clinical Oncology871 citations Open access
Semantic Scholar
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
M. Roemer, R. Advani, A. Ligon, Y. Natkunam +13 more
2016Journal of Clinical Oncology717 citations Open access
Semantic Scholar
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
P. Armand, A. Engert, A. Younes, M. Fanale +15 more
2018Journal of Clinical Oncology625 citations Open access
Semantic Scholar
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
P. Armand, M. Shipp, V. Ribrag, J. Michot +7 more
2016Journal of Clinical Oncology617 citations Open access
Semantic Scholar
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
Lakshmi Nayak, F. Iwamoto, A. LaCasce, S. Mukundan +5 more
2017Blood423 citations Open access
Semantic Scholar
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
M. Roemer, R. Redd, F. Cader, Christine J. Pak +25 more
2018Journal of Clinical Oncology326 citations Open access
Semantic Scholar
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
S. Ansell, M. Minnema, P. Johnson, J. Timmerman +14 more
2019Journal of Clinical Oncology318 citations Open access
Semantic Scholar
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
Christopher D. Carey, D. Gusenleitner, Mikel Lipschitz, M. Roemer +10 more
2017Blood309 citations Open access
Semantic Scholar
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: Two-year follow-up of KEYNOTE-087.
Robert Chen, P. Zinzani, Hun Lee, P. Armand +14 more
2019Blood302 citations Open access
Semantic Scholar
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
P. Zinzani, V. Ribrag, C. Moskowitz, J. Michot +6 more
2017Blood268 citations Open access
Semantic Scholar
NLRC5/MHC class I transactivator is a target for immune evasion in cancer
S. Yoshihama, J. Roszik, Isaac Downs, T. Meissner +6 more
2016Proceedings of the National Academy of Sciences of the United States of America265 citations Open access
Semantic Scholar
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
P. Armand, S. Rodig, V. Melnichenko, C. Thieblemont +25 more
2019Journal of Clinical Oncology232 citations Open access
Semantic Scholar
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
R. Ramchandren, E. Domingo-Domènech, A. Rueda, M. Trněný +16 more
2019Journal of Clinical Oncology212 citations Open access
Semantic Scholar
Nivolumab-AVD in Advanced Stage Classic Hodgkin Lymphoma
Alex F. Herrera, M. LeBlanc, S. Castellino, Hongli Li +43 more
2024New England Journal of Medicine210 citations Open access
Semantic Scholar
PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation.
P. Armand, Yi-Bin Chen, R. Redd, R. Joyce +21 more
2018Blood166 citations Open access
Semantic Scholar
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.
K. Wienand, B. Chapuy, Chip Stewart, Andrew J. Dunford +18 more
2019Blood Advances148 citations Open access
Semantic Scholar
The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative.
Sanjay S. Patel, J. Weirather, Mikel Lipschitz, Ana Lako +5 more
2019Blood132 citations Open access
Semantic Scholar
A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in Patients with Classical Hodgkin Lymphoma
F. Cader, Xi-Hao Hu, Walter L. Goh, K. Wienand +14 more
2020Nature Medicine126 citations Open access
Semantic Scholar
Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment.
F. Cader, R. Schackmann, Xi-Hao Hu, K. Wienand +13 more
2018Blood120 citations Open access
Semantic Scholar
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
Philippe Armand, P. Zinzani, Hun Lee, N. Johnson +14 more
2023Blood101 citations Open access
Semantic Scholar
Genomic Analyses of PMBL Reveal New Drivers and Mechanisms of Sensitivity to PD-1 Blockade.
B. Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim +12 more
2019Blood96 citations Open access
Semantic Scholar
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
S. Ansell, P. Bröckelmann, G. von Keudell, Hun Lee +17 more
2023Blood Advances94 citations Open access
Semantic Scholar
Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
K. Bojarczuk, K. Wienand, J. Ryan, Lin-Feng Chen +7 more
2018Blood85 citations Open access
Semantic Scholar
Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
W. R. Liu, M. Shipp
2017Blood74 citations Open access
Semantic Scholar
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
P. Zinzani, C. Thieblemont, V. Melnichenko, K. Bouabdallah +14 more
2023Blood68 citations Open access
Semantic Scholar
Combined anti-VEGF and anti–CTLA-4 therapy elicits humoral immunity to galectin-1 which is associated with favorable clinical outcomes
Xin-Qi Wu, Jingjing Li, E. Connolly, X. Liao +11 more
2017Cancer immunology research64 citations Open access
Semantic Scholar
MAPS: pathologist-level cell type annotation from tissue images through machine learning
M. Shaban, Yun-Hao Bai, Hua-Ying Qiu, Shulin Mao +11 more
2023bioRxiv56 citations Open access
Semantic Scholar
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation.
M. Frigault, P. Armand, R. Redd, Erin Jeter +22 more
2020Blood Advances55 citations Open access
Semantic Scholar
Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma.
G. Griffin, J. Weirather, M. Roemer, Mikel Lipschitz +27 more
2020Blood49 citations Open access
Semantic Scholar
Mass cytometry of Hodgkin lymphoma reveals a CD 4 + exhausted T-effector and T-regulatory cell rich microenvironment
F. Cader, R. Schackmann, Xi-Hao Hu, K. Wienand +14 more
201844 citations
Semantic Scholar
Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging
Kyle T. Wright, J. Weirather, Si-Zun Jiang, Katrina Z Kao +4 more
2023Blood Advances35 citations Open access
Semantic Scholar
DLBclass: A Probabilistic Molecular Classifier to Guide Clinical Investigation and Practice in DLBCL.
B. Chapuy, Timothy Wood, Chip Stewart, Andrew J. Dunford +13 more
2024Blood31 citations
Semantic Scholar
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas
Lin-Feng Chen, J. Ouyang, K. Wienand, K. Bojarczuk +8 more
2019Haematologica31 citations Open access
Semantic Scholar
Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
B. Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim +42 more
2018Nature Medicine27 citations Open access
Semantic Scholar
Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma
P. Zinzani, Hun Lee, P. Armand, N. Johnson +14 more
2018Blood26 citations Open access
Semantic Scholar
Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies
P. Armand, S. Rodig, V. Melnichenko, C. Thieblemont +25 more
2018Blood24 citations Open access
Semantic Scholar
Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.
Robert Chen, P. Zinzani, M. Fanale, P. Armand +9 more
201623 citations
Semantic Scholar
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation
R. Merryman, R. Redd, E. Taranto, Gulrayz Ahmed +23 more
2022Blood Advances21 citations Open access
Semantic Scholar
NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW‐UP OF THE PHASE 2 CHECKMATE 205 TRIAL
M. Fanale, A. Engert, A. Younes, P. Armand +16 more
201721 citations Open access
Semantic Scholar
Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)
P. Armand, P. Zinzani, Hun Lee, N. Johnson +14 more
2021Blood20 citations Open access
Semantic Scholar
NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY
S. Ansell, P. Bröckelmann, G. von Keudell, Hun Lee +16 more
2021Hematological Oncology20 citations Open access
Semantic Scholar
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
A. Herrera, M. LeBlanc, S. Castellino, H. Li +42 more
2023Hematological Oncology19 citations Open access
Semantic Scholar
SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A. Herrera, Hongli Li, S. Castellino, S. Rutherford +17 more
202019 citations Open access
Semantic Scholar
Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study
P. Armand, A. Engert, A. Younes, Hun Lee +14 more
2018Blood19 citations
Semantic Scholar
Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial
P. Zinzani, C. Thieblemont, V. Melnichenko, D. Osmanov +14 more
201719 citations Open access
Semantic Scholar
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
M. Boyiadzis, M. Bishop, R. Abonour, K. Anderson +44 more
2016Journal of Immunotherapy for Cancer19 citations Open access
Semantic Scholar
Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma
J. Paczkowska, Ming Tang, Kyle T. Wright, Li Song +19 more
2024Nature Communications18 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Armand×26
Invite
P. Armand — researcher profile on SciRah
S. Rodig×22
Invite
S. Rodig — researcher profile on SciRah
P. Zinzani×18
Invite
P. Zinzani — researcher profile on SciRah
R. Redd×17
Invite
R. Redd — researcher profile on SciRah

×13

Invite

B. Chapuy — researcher profile on SciRah

Invite

D. Neuberg — researcher profile on SciRah

Invite

V. Ribrag — researcher profile on SciRah

C. Moskowitz×10

Invite

C. Moskowitz — researcher profile on SciRah

Invite

J. Ouyang — researcher profile on SciRah

Invite

S. Ansell — researcher profile on SciRah

Invite

M. Roemer — researcher profile on SciRah

Invite

A. Ligon — researcher profile on SciRah